Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1260

1.

Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice.

Hebb AL, Robertson HA, Denovan-Wright EM.

Eur Neuropsychopharmacol. 2008 May;18(5):339-63. Epub 2007 Oct 29.

PMID:
17913473
2.

Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.

Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, Schmidt CJ.

Neuropharmacology. 2006 Aug;51(2):386-96. Epub 2006 Jun 15.

PMID:
16780899
3.

PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model.

Giralt A, Saavedra A, Carretón O, Arumí H, Tyebji S, Alberch J, Pérez-Navarro E.

Hippocampus. 2013 Aug;23(8):684-95. doi: 10.1002/hipo.22128. Epub 2013 Apr 29.

PMID:
23576401
4.

Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.

Giampà C, Middei S, Patassini S, Borreca A, Marullo F, Laurenti D, Bernardi G, Ammassari-Teule M, Fusco FR.

Eur J Neurosci. 2009 Mar;29(5):902-10. doi: 10.1111/j.1460-9568.2009.06649.x.

PMID:
19291221
5.

Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.

Leuti A, Laurenti D, Giampà C, Montagna E, Dato C, Anzilotti S, Melone MA, Bernardi G, Fusco FR.

Neurobiol Dis. 2013 Apr;52:104-16. doi: 10.1016/j.nbd.2012.11.016. Epub 2012 Dec 7.

PMID:
23220622
6.

Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function.

Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS, Schmidt CJ.

Neuropharmacology. 2006 Aug;51(2):374-85. Epub 2006 Jun 12.

PMID:
16769090
7.

Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.

Giampà C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR.

PLoS One. 2010 Oct 15;5(10):e13417. doi: 10.1371/journal.pone.0013417.

8.

Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease.

Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR.

J Neurosci. 2005 Apr 20;25(16):4169-80.

9.

Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background.

Siuciak JA, McCarthy SA, Chapin DS, Martin AN, Harms JF, Schmidt CJ.

Neuropharmacology. 2008 Feb;54(2):417-27. Epub 2007 Dec 3.

PMID:
18061215
10.
11.

Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme.

Siuciak JA, McCarthy SA, Chapin DS, Reed TM, Vorhees CV, Repaske DR.

Neuropharmacology. 2007 Jul;53(1):113-24. Epub 2007 Apr 29.

PMID:
17559891
12.

Complexin II is essential for normal neurological function in mice.

Glynn D, Bortnick RA, Morton AJ.

Hum Mol Genet. 2003 Oct 1;12(19):2431-48. Epub 2003 Jul 29.

PMID:
12915444
13.

Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's disease.

Emerich DF, Cain CK, Greco C, Saydoff JA, Hu ZY, Liu H, Lindner MD.

Cell Transplant. 1997 May-Jun;6(3):249-66.

PMID:
9171158
14.

Contrasting effects of acute and chronic treatment with imipramine and fluoxetine on inhibitory avoidance and escape responses in mice exposed to the elevated T-maze.

Gomes KS, de Carvalho-Netto EF, Monte KC, Acco B, Nogueira PJ, Nunes-de-Souza RL.

Brain Res Bull. 2009 Mar 30;78(6):323-7. doi: 10.1016/j.brainresbull.2008.11.003. Epub 2008 Nov 29.

PMID:
19047015
15.

Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.

Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, Hage T, Comery TA, Brandon NJ.

J Pharmacol Exp Ther. 2009 Nov;331(2):574-90. doi: 10.1124/jpet.109.155994. Epub 2009 Aug 6.

16.

Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.

Kleiman RJ, Kimmel LH, Bove SE, Lanz TA, Harms JF, Romegialli A, Miller KS, Willis A, des Etages S, Kuhn M, Schmidt CJ.

J Pharmacol Exp Ther. 2011 Jan;336(1):64-76. doi: 10.1124/jpet.110.173294. Epub 2010 Oct 5.

17.

Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.

Domenici MR, Scattoni ML, Martire A, Lastoria G, Potenza RL, Borioni A, Venerosi A, Calamandrei G, Popoli P.

Neurobiol Dis. 2007 Nov;28(2):197-205. Epub 2007 Jul 24.

PMID:
17720507
18.

Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease.

Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN.

Neuroscience. 2008 Oct 28;156(4):830-40. doi: 10.1016/j.neuroscience.2008.08.035. Epub 2008 Sep 9.

PMID:
18817851
19.

Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.

Denovan-Wright EM, Attis M, Rodriguez-Lebron E, Mandel RJ.

J Neurosci Res. 2008 Jun;86(8):1748-57. doi: 10.1002/jnr.21636.

20.

Mice transgenic for reduced folate carrier: an animal model of Down syndrome?

Höger J, Patterson D, Höger H, Shim KS, Bubna-Littitz H, Lubec G.

Amino Acids. 2009 Feb;36(2):349-57. doi: 10.1007/s00726-008-0091-0. Epub 2008 Apr 15.

PMID:
18414976

Supplemental Content

Support Center